Oxford Cannabinoid Technologies Holdings (LON:OCTP)

Webinar for private investors

Thursday 10th June at 1pm

Register here for free: https://us02web.zoom.us/webinar/register/1316221058814/WN_RIzq0rv9SQuVHlhGwRcuhQ

https://www.oxcantech.com/

Oxford Cannabinoid Technologies Holdings plc is a UK-based next generation cannabis pharmaceutical company focussed on the development cannabinoid-based prescription medicines to target indications in the £42.5bn pain market, with regulatory marketing approval from agencies including the FDA, EMA and MHRA. Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs.

To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.

Neil Mahapatra, Executive Chairman


Neil Mahapatra is a Co-founder of OCT and serves as Executive Chairman of the Company, having conceptualised the business and directly hired the other Executive Directors. Neil has nearly two decades of experience in business and the investment industry. He began his career in investment banking at Morgan Stanley International plc, in healthcare corporate finance and UK equity capital markets before becoming a private equity executive at J. Rothschild Capital Management Limited, where he led private investments for the family office of Lord Rothschild and RIT Capital Partners plc.

Neil is a known and respected leader in the European cannabis industry. Through KCP, Neil sponsored and launched the End our Pain campaign, a prominent campaign that was instrumental in effecting the UK government reforms to medical cannabis legislation in 2018. Outside of business, Neil serves as Chair of the board of a leading global architecture and design non-profit firm, the MASS Design Group, where he also sits on the finance and governance committees. Neil is also a trustee of the Oxford Union Literary and Debating Trust. Neil is a known and respected leader in the European cannabis industry. Through KCP, Neil sponsored and launched the End our Pain campaign, a prominent campaign that was instrumental in effecting the UK government reforms to medical cannabis legislation in 2018.

Outside of business, Neil serves as Chair of the board of…

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here